Clinical Trials Logo

Clinical Trial Summary

Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment in Stage III or IV melanoma.

Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease control rates.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02200562
Study type Interventional
Source University of Utah
Contact
Status Terminated
Phase Phase 1
Start date December 2014
Completion date January 20, 2017

See also
  Status Clinical Trial Phase
Withdrawn NCT01455103 - Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma Phase 1